Authors
|
Study
|
Type of study
|
No. IA patients
|
Ages (y)
|
Sites
|
Metastases
|
No. Preoperative CDDP courses
|
Time of surgery
|
>90% TN
|
Survival
|
EFS
|
| Winkler et al.28 and Fuchs et al.5 |
COSS 1986 |
Nonrandomized, 2 arms |
50 |
<40 |
All |
Included |
2 |
Week 11 |
68% |
67% at 10 y |
63% at 10 y |
| Ferrari et al.26 |
IOR-OS 2 |
Single arm |
164 |
<40 |
Extremity |
Excluded |
2 |
Week 8 |
NA |
72% at 8 y |
63% at 8 y |
| Ferrari et al.26 |
IOR-OS 3 |
Randomized, 2 arms |
59 |
<40 |
Extremity |
Excluded |
2 |
Week 8 |
64% |
61% at 8 y |
54% at 8 y |
| Rha et al.27 |
Korea |
Single arm |
37 |
8–41 |
Extremity |
? |
3 |
Week 9 |
75% |
78% at 3 y |
55% at 3 y |
| Bacci et al.25 |
3-drug study |
Randomized, 2 arms |
40 |
<40 |
Extremity |
Included |
2 |
Week 8–9 |
77% |
NA |
26% at 5 y |
| Bacci et al.25 |
4-drug study |
Randomized, 2 arms |
72 |
<40 |
Extremity |
Included |
2 |
Week 10 |
80% |
NA |
61% at 5 y |
| Wilkins et al. |
This study |
Single arm |
47 |
<21 |
Extremity |
Excluded |
3–5 (response dependent) |
Wk 10–16 (response dependent) |
87% |
92% at 10 y |
84% at 10 y |
|
| IA, intra-arterial; CDDP, cisplatin; TN, tumor necrosis; EFS, event-free survival; NA, not available; COSS, the Cooperative (German-Austrian-Swiss) Osteosarcoma Study; IOR-OS, Istituto Ortopedico Rizzoli. |
|